Decoupled calcium homeostasis and signaling associated with cytoskeletal instability in YWHAG R132C induced pluripotent stem cell-derived cortical neurons

Using an isogenic iPSC model, this study reveals that the YWHAG R132C mutation causes cytoskeletal instability and a decoupling of calcium homeostasis from signaling in cortical neurons, characterized by elevated baseline calcium and reduced network activity that are partially modifiable by ROCK pathway inhibition and lovastatin treatment.

The Gist

The Big Picture: A Broken Scaffolding Crew

Imagine the brain as a bustling construction site. To build a functional city (a healthy brain), you need strong scaffolding to hold everything in place while workers lay the bricks. In our brain cells, this "scaffolding" is made of proteins called the cytoskeleton.

One specific worker on this crew is a protein named 14-3-3γ (encoded by the YWHAG gene). Its job is to act like a foreman, holding the scaffolding together and making sure the construction crew (signaling pathways) knows what to do.

YWHAG Syndrome is a rare, severe childhood epilepsy caused by a typo in the instruction manual for this foreman. Specifically, this study looked at a mutation called R132C. Because of this typo, the foreman is defective, and the construction site starts to fall apart.

Until now, scientists knew the site was broken, but they didn't know exactly how or if there was a way to fix it. This study used a high-tech "mini-brain" grown in a dish to figure it out.

---

The Investigation: What Went Wrong?

The researchers grew brain cells from stem cells. They had two groups:

1. The Control Group: Cells with the perfect, healthy foreman.
2. The Mutant Group: Cells with the broken foreman (R132C mutation).

Here is what they found:

1. The Scaffolding is Wobbly

In the mutant cells, the "scaffolding" (cytoskeleton) was unstable.

• The Analogy: Imagine trying to build a tower of Jenga blocks, but the blocks are slippery. In the mutant cells, the blocks (proteins) couldn't stick together properly. When the researchers tried to gently wash the cells (like a light rain), the mutant cells fell apart, while the healthy cells stayed standing.
• The Result: The mutant neurons were smaller and had trouble growing their "branches" (neurites), which are needed to talk to other brain cells.

2. The Electrical Chaos (Calcium Homeostasis)

Brain cells communicate using electricity, which relies on a chemical called calcium. Think of calcium as the "fuel" for the brain's electrical signals.

• The Problem: In the mutant cells, the "fuel tank" was leaking. The baseline level of calcium was too high (like a tank that is always overfilled).
• The Spark: Because the tank was so full and the pipes were clogged, the cells couldn't fire their electrical "sparks" (spikes) properly. They fired fewer sparks, and the sparks were weaker.
• The Paradox: Usually, epilepsy is caused by too much firing. Here, the cells were actually under-firing (hypoexcitable) because their internal environment was so chaotic. It's like a car engine that is flooded with gas; it sputters and won't start, even though there is plenty of fuel.

3. The Confused Foreman (The ROCK Pathway)

The researchers found that a signaling pathway called ROCK was trying to help, but it was confused.

• Early Stage: At first, ROCK tried to tighten the scaffolding to compensate for the broken foreman.
• Later Stage: As the cells got older, ROCK gave up and stopped working, causing the scaffolding to collapse completely.
• The Test: When the researchers used a drug (Y27632) to stop ROCK entirely, the mutant cells got even worse. This proved that the cells were desperately relying on ROCK to keep their structure together.

---

The Solution: A "Magic" Pill?

The researchers wanted to see if they could fix the wobbly scaffolding and the leaking fuel tank. They tried a drug called Lovastatin.

• What is Lovastatin? You might know it as a cholesterol medication (like a generic statin). But in this context, it acts like a glue for the cell's internal structure. It helps stabilize the proteins that make up the scaffolding.

The Results of the Lovastatin Treatment:

1. The Scaffolding Got Sturdy: When they treated the mutant cells with Lovastatin, the "slippery blocks" suddenly stuck together again. The cells stopped falling apart when washed.
2. The Fuel Tank Leaked Less: The high baseline calcium levels dropped back down toward normal.
3. The Spark Didn't Fully Return: Here is the twist. While the "leak" was fixed, the cells still couldn't fire their electrical sparks as well as healthy cells. The frequency and strength of the sparks remained low.

The "Decoupling" Discovery:
This is the most important finding. The study showed that stability (keeping the cell from falling apart) and signaling (firing electrical sparks) are two different things that got "uncoupled."

• Analogy: Imagine a house with a shaky foundation. You pour concrete to fix the foundation (Lovastatin). The house is now stable and won't collapse. However, the electricity inside the house is still flickering because the wiring was damaged during the collapse. You fixed the structure, but the electrical signal is still broken.

---

Why Does This Matter?

1. A New Way to Treat Epilepsy: Most epilepsy drugs try to stop the brain from firing too much. But in YWHAG Syndrome, the problem is that the brain can't fire correctly because the structure is broken. This study suggests that fixing the structure (stabilizing the cytoskeleton) might be a better first step than just trying to stop the seizures.
2. Repurposing an Old Drug: Lovastatin is already an FDA-approved, safe drug used for cholesterol. If it can stabilize brain cells in this rare disease, it could be a fast-track treatment option without needing to invent a new drug from scratch.
3. Understanding the Brain: This research shows us that the "scaffolding" of a brain cell is directly connected to its electrical health. If the structure is weak, the brain's communication system fails, leading to developmental delays and seizures.

Summary

Think of the brain cell as a house. In YWHAG Syndrome, the walls are made of weak clay.

• The Mutation: The clay is crumbling.
• The Symptom: The house is unstable, and the lights (electricity) are flickering.
• The Fix: The researchers found a special glue (Lovastatin) that hardens the clay.
• The Outcome: The house stops crumbling (stability is restored), but the lights are still dim.
• The Future: Now that we know the house is stable, we can work on fixing the wiring (the electrical signaling) to get the lights shining bright again. This gives doctors a clear roadmap for treating this rare and devastating condition.

Technical Summary

1. Problem Statement

YWHAG Syndrome (Developmental and Epileptic Encephalopathy 56, DEE56) is an ultra-rare childhood epilepsy characterized by early-onset seizures, drug-resistant epilepsy, and neurodevelopmental delays. It is caused by de novo mutations in the YWHAG gene, which encodes the 14-3-3γ protein.

• Knowledge Gap: While 14-3-3γ is known to interact with neurodevelopmental signaling pathways (e.g., ROCK, RAF1, PKC) and is crucial for neurite outgrowth and neuronal migration, the specific molecular mechanisms by which YWHAG mutations (specifically the R132C mutation) disrupt neuronal function and survival remain poorly understood.
• Therapeutic Void: There are currently no therapeutic interventions available for patients with YWHAG Syndrome.

2. Methodology

The authors utilized an isogenic human induced pluripotent stem cell (iPSC) model to differentiate cortical excitatory neurons, comparing wild-type (WT) controls with neurons carrying the heterozygous YWHAG^R132C/+ mutation.

• Cell Model: iPSC line iP11NK (ALSTEM) edited to contain the R132C mutation, with a Tet-ON::NGN2 expression cassette for rapid differentiation into cortical neurons.
• Differentiation: NGN2-induced differentiation protocol to generate cortical excitatory neurons.
• Phenotypic Characterization:
  • Immunocytochemistry: Staining for neuronal markers (NeuN, MAP2, SOX2) and apoptosis markers (Caspase-3).
  • Calcium Imaging: Live-cell imaging using Fluo-4 AM to quantify calcium baseline, spike frequency, and amplitude.
  • Multielectrode Array (MEA): Recording of network activity and firing rates.
  • Transcriptomics: Bulk RNA sequencing (RNA-seq) at early (DIV 7) and mature (DIV 30) stages to identify differentially expressed genes (DEGs) and Gene Ontology (GO) enrichment.
  • Protein Stability Assays: Western blotting following Trypsin-EDTA treatment to assess cytoskeletal stability (susceptibility to detachment-induced degradation).
• Pharmacological Interventions:
  • Y27632: A direct ROCK1/2 inhibitor.
  • Lovastatin: An HMG-CoA reductase inhibitor that modulates the ROCK pathway via upstream prenylation inhibition and affects L-type calcium channels.

3. Key Contributions

• First Isogenic iPSC Model: Established a robust cellular model for YWHAG Syndrome to study the R132C mutation's specific effects on human cortical neurons.
• Mechanistic Insight: Identified a biphasic dysregulation of the ROCK pathway that leads to cytoskeletal instability and altered calcium homeostasis.
• Decoupling Phenomenon: Demonstrated that cytoskeletal instability in mutant neurons leads to a "decoupling" of calcium homeostasis (baseline levels) from calcium signaling (spike frequency/amplitude).
• Therapeutic Proof-of-Concept: Showed that lovastatin can partially rescue cytoskeletal stability and normalize calcium baselines, suggesting a potential repurposing strategy for YWHAG Syndrome.

4. Key Results

A. Cytoskeletal and Morphological Defects

• Reduced Neurite Outgrowth: YWHAG^R132C/+ neurons exhibited a significant reduction in the area of MAP2/NeuN-positive neurons compared to controls, indicating impaired neurite outgrowth.
• Cytoskeletal Instability: When exposed to Trypsin-EDTA (a stressor that detaches cells), YWHAG^R132C/+ neurons showed a catastrophic loss of cytoskeletal proteins (14-3-3γ, α-Tubulin, β-actin) and HSP70. This loss was partially rescued by 12 hours of lovastatin treatment, suggesting the mutation compromises protein stability rather than just synthesis.

B. Calcium Homeostasis and Signaling Defects

• Elevated Baseline: Mutant neurons displayed a significantly elevated intracellular calcium baseline starting as early as DIV 18 and persisting through DIV 72.
• Reduced Signaling: Despite high baseline calcium, mutant neurons showed reduced frequency and amplitude of calcium spikes and lower overall network activity (MEA data).
• Decoupling: The data suggests a dissociation where the mechanisms maintaining calcium levels are distinct from those generating calcium transients (spikes).

C. Transcriptomic Analysis (ROCK Pathway)

• Biphasic Response:
  • Early Stage (DIV 7): Widespread upregulation of ROCK pathway genes (RhoGEFs, ROCK1/2, LIMK-Cofilin, focal adhesion proteins), suggesting an initial compensatory increase in cytoskeletal stiffness.
  • Mature Stage (DIV 30): Drastic downregulation of these same genes, correlating with the observed cytoskeletal instability and protein loss.
• GO Enrichment: Early DEGs were enriched for ion channels and cell adhesion; mature DEGs were depleted of structural cytoskeleton components and signaling receptors.

D. Pharmacological Interventions

• Y27632 (Direct ROCK Inhibitor): Direct inhibition of ROCK in mutant neurons increased the calcium baseline further, confirming that ROCK activity is required to maintain calcium homeostasis in the mutant context.
• Lovastatin:
  • Cytoskeleton: Partially restored protein levels of 14-3-3γ and cytoskeletal markers in Trypsin-treated mutant neurons.
  • Calcium: Significantly reduced the elevated calcium baseline in mutant neurons (partial rescue).
  • Limitation: Lovastatin did not rescue the reduced frequency or amplitude of calcium spikes. This confirms the "decoupling" hypothesis: lovastatin stabilizes the cytoskeleton and lowers the baseline but cannot restore the signaling dynamics.

5. Significance

• Mechanistic Understanding: The study elucidates that YWHAG mutations do not merely cause a loss of function but lead to a complex, time-dependent failure of the ROCK-cytoskeleton axis, resulting in a state of "cytoskeletal fragility" that disrupts calcium regulation.
• Therapeutic Targeting: The identification of lovastatin as a compound that stabilizes the cytoskeleton and normalizes calcium baselines provides a promising, FDA-approved candidate for repurposing in YWHAG Syndrome.
• Broader Implications: Since 14-3-3γ is implicated in other neurodevelopmental disorders (Down Syndrome, Williams Syndrome) and neurodegenerative diseases (Alzheimer's, Parkinson's), the findings regarding cytoskeletal-calcium decoupling may offer insights into the pathophysiology of these broader conditions.
• Future Directions: The work establishes a platform for screening additional small molecules that target the ROCK pathway or cytoskeletal stability to restore full neuronal signaling in YWHAG Syndrome.